Allergy/asthma and cystic fibrosis (CF) focus of awareness in May

This press release is also available in French.

OTTAWA New research initiatives announced just in time for both Allergy/Asthma and Cystic Fibrosis (CF) Awareness Months will focus on developing a better understanding of the ways in which people respond to exposure to infectious agents in the lungs.

Understanding the role of the immune system in lung disease is the focus of new research projects funded through a $4.5 million partnership between the Canadian Institutes of Health Research (CIHR) Institutes of Infection and Immunity and Cardiovascular and Respiratory Health, AllerGen, a Network of Centres of Excellence based at McMaster University in Hamilton, Ontario, and the Canadian Cystic Fibrosis Foundation (CCFF). CIHR funding for this initiative is part of a larger package recently announced by the Minister of Health. These projects will be conducted at a number of Canadian universities and associated hospitals, and will bring together leading experts from a range of scientific disciplines to network on key research questions in this area.

The mucous membranes of the respiratory tract represent a major site of exposure of humans to allergens and infectious agents, yet much of our knowledge of the immune response comes from studying generalized infections and infections at non-mucosal sites. The lung represents a particularly important and understudied site of this interaction between infectious agent and its host.

Statistics from the World Health Organization reported 4.4 million deaths throughout the world in 2003 resulting from acute bacterial and viral lower respiratory tract infections. While many people suffering from lung infection do not die, the lives of millions of Canadians are affected every year, with major impacts on health care system costs and loss of productivity. A recent study has suggested that uncontrolled asthma cases in adults an

Contact: Jasmine Sharma
Canadian Institutes of Health Research

Page: 1 2

Related biology news :

1. Chinese medicinal compound stops formation of cysts in polycystic kidney disease in lab
2. Key found to kill cystic fibrosis superbug
3. Clues to gene expression in cystic fibrosis will guide research
4. Triptolide: A potential drug for polycystic kidney disease
5. Diabetes gene may be linked to polycystic ovary syndrome
6. Researchers identify molecule that causes destructive lung inflammation in cystic fibrosis patients
7. Newly discovered proteins associated with cystic fibrosis
8. Study reveals how cells destroy faulty proteins in cystic fibrosis
9. UF study sheds light on cystic fibrosis-related diabetes
10. Discovery could aid fight against cystic fibrosis infection
11. Polycystic kidney disease: MRI provides an early alert to progression

Post Your Comments:

(Date:8/26/2020)... ... August 24, 2020 , ... Elgia ... inflammatory and fibrotic diseases, today announced that Dr. Stacie Canan has joined the ... Dr. Canan previously served as Executive Director of Global Health at Bristol Myers ...
(Date:8/23/2020)... (PRWEB) , ... August 21, 2020 , ... ... Rigaku Corporation has been published and is now available on the company’s ... X-ray diffraction—serves the X-ray analysis community, presenting current news and crystallographic research. ...
(Date:8/21/2020)... (PRWEB) , ... August 20, 2020 , ... ... that Hassan Movahhed , a Clinical Operations executive with expertise in clinical ... has joined the firm as an Expert Consultant. Throughout his career, Mr. Movahhed ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Slone ... companies, has announced the placement of Julianne Averill , CPA, as Chief ... all financial operations and implementing key business strategies to accelerate Alveo’s growth as ...
(Date:8/15/2020)... ... August 13, 2020 , ... True Terpenes , the leading platform ... Advisory Board (SAB) to research the medical potential of terpenes and the potential ... with terpenes. The board is focused on expanding the recently launched line of effects-based ...
(Date:8/12/2020)... Mass. (PRWEB) , ... August 11, 2020 , ... ... $300,000 a year to expand the Facioscapulohumeral Muscular Dystrophy Clinical Trial Research ... in 2021 and 2022. The network is a consortium of academic research centers ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 12, 2020 , ... ... Group, Inc. (EMMA International), a global leader in FDA compliance consulting has ... the nation’s fastest-growing private companies. The list represents a unique look at the ...
Breaking Biology Technology:
Cached News: